Inhibikase Therapeutics, Inc.
IKT · Nasdaq · SIC 2836: Biological Products, (No Diagnostic Substances)
Business Summary
3 Item 1A. Risk Factors 21 Item 1B. Unresolved Staff Comments 70 Item 1C. Cybersecurity 70 Item 2. Properties 71 Item 3. Legal Proceedings 71 Item 4. Mine Safety Disclosures 71 PART II Item 5. Market for Registrants Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities 72 Item 6. [Reserved] 72 Item 7. Managements Discussion and Analysis of Financial Condition and Results of Operations 73 Item 7A. Quantitative and Qualitative Disclosures About Market Risk 81 Item 8....
Next Earnings
Q2 FY2026 — expected 2026-08-09
Key Facts from Earnings Calls
| Type | Subject | Detail | Quarter |
|---|
| topic_mention | IKT | discussed_in_filing Cybersecurity | |
| topic_mention | IKT | discussed_in_filing Cybersecurity | |
| topic_mention | IKT | discussed_in_filing Cybersecurity | |
| topic_mention | IKT | discussed_in_filing Cybersecurity | |
Annual Reports (10-K)
| Filed | Period | Accession | Source | Full Text |
|---|
| 2026-03-26 | 2025-12-31 | 0001193125-26-126371 | EDGAR | 104K words |
| 2025-03-27 | 2024-12-31 | 0000950170-25-046096 | EDGAR | — |
| 2024-03-27 | 2023-12-31 | 0000950170-24-037160 | EDGAR | — |
| 2023-03-31 | 2022-12-31 | 0000950170-23-011133 | EDGAR | — |
| 2022-03-31 | 2021-12-31 | 0000950170-22-005203 | EDGAR | — |
| 2021-03-31 | 2020-12-31 | 0001564590-21-016996 | EDGAR | — |
Quarterly Reports (10-Q)
| Filed | Period | Accession | Source | Full Text |
|---|
| 2025-11-14 | 2025-09-30 | 0001193125-25-283169 | EDGAR | 29K words |
| 2025-08-14 | 2025-06-30 | 0001193125-25-180899 | EDGAR | — |
| 2025-05-14 | 2025-03-31 | 0000950170-25-071635 | EDGAR | — |
| 2024-11-14 | 2024-09-30 | 0000950170-24-126766 | EDGAR | — |
| 2024-08-14 | 2024-06-30 | 0000950170-24-097022 | EDGAR | — |
| 2024-05-15 | 2024-03-31 | 0000950170-24-060579 | EDGAR | — |
| 2023-11-14 | 2023-09-30 | 0000950170-23-063713 | EDGAR | — |
| 2023-08-14 | 2023-06-30 | 0000950170-23-042389 | EDGAR | — |
| 2023-05-15 | 2023-03-31 | 0000950170-23-021974 | EDGAR | — |
| 2022-11-14 | 2022-09-30 | 0000950170-22-025011 | EDGAR | — |
| 2022-08-12 | 2022-06-30 | 0000950170-22-017140 | EDGAR | — |
| 2022-05-16 | 2022-03-31 | 0000950170-22-010085 | EDGAR | — |
Recent Current Reports (8-K)
| Filed | Accession | Source | Full Text |
|---|
| 2026-03-26 | 0001193125-26-126322 | EDGAR | 3K words |
| 2025-12-19 | 0001193125-25-326916 | EDGAR | — |
| 2025-11-21 | 0001193125-25-291443 | EDGAR | — |
| 2025-11-20 | 0001193125-25-289768 | EDGAR | — |
| 2025-11-14 | 0001193125-25-283075 | EDGAR | — |
| 2025-08-14 | 0001193125-25-180889 | EDGAR | — |
| 2025-06-30 | 0001193125-25-152767 | EDGAR | — |
| 2025-05-14 | 0001193125-25-119939 | EDGAR | — |
| 2025-04-14 | 0001193125-25-079656 | EDGAR | — |
| 2025-03-27 | 0001193125-25-065511 | EDGAR | — |
117 total filings indexed. 89 additional filings (S-1, DEF 14A, etc.) View all (JSON) · SEC EDGAR
Sector Peers
Company Identity
| CIK | 0001750149 |
| Ticker | IKT |
| Exchange | Nasdaq |
| SIC | 2836: Biological Products, (No Diagnostic Substances) |
| Incorporated | DE |
Get More Data
This is the free public profile. For structured JSON with full provenance chain, use the API:
JSON Profile
Stock Quote
AI Readiness Report
Origin Provenance
page leaf: 20a9971d6ff4142463b9b1af7ee82fad5cfa3b50f8d9d327ffafd497a1e651d4
parent: d087197dacd9fd42d04c7e2b55a766c45a303d277bebd84410a6487134f74907
content hash: 1f15f3ccdef015ad28bd19b091bd900854473899ac92798536981d6a4d0d60ce
signed: 2026-04-13T04:45:39.657Z
sources: 18 verified data leaves
chain: SEC.gov PEM → origin.rootz.global extraction → this page
verify: sha256(content_hash + parent + timestamp) = leaf